[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Ado-trastuzumab emtansine",
            "Result": [
                "Score: -2  \nReasoning:  \nAll five abstracts consistently report that Ado-trastuzumab emtansine (T-DM1) is associated with worse survival (both progression-free survival [PFS] and overall survival [OS]) and increased toxicity in HER2-positive breast cancer cohorts, contradicting the hypothesis that T-DM1 has \u201cno effect.\u201d For instance:  \n\n\u2022 PMID: 358559 arrives at \u201csignificantly worse survival outcomes and higher toxicity\u201d with elevated grade \u22653 adverse events.  \n\u2022 PMID: 874986 also shows \u201csignificantly shorter PFS and OS\u201d and increased toxicity in T-DM1\u2013treated patients.  \n\u2022 PMID: 140087 reflects a similar pattern of reduced survival and heightened rates of grade \u22653 AEs with T-DM1.  \n\u2022 PMID: 677364 likewise notes inferior survival outcomes and more frequent severe toxicities.  \n\u2022 PMID: 308567 corroborates these findings, reporting \u201csignificantly worse survival, higher toxicity, and inferior quality of life.\u201d  \n\nTogether, these data indicate T-DM1 exerts a negative impact\u2014i.e., a real and detrimental effect\u2014on patient outcomes, thereby refuting the hypothesis that T-DM1 has no effect on breast cancer patient outcomes."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 358559. **Title: Adverse Outcomes Associated with Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer (MBC) following prior trastuzumab and taxane therapy. While clinical trials have demonstrated efficacy, real-world data suggest potential detrimental effects in certain patient subgroups. This study evaluates the impact of T-DM1 on survival and toxicity outcomes in a large, unselected cohort.  \n\n**Methods:** We conducted a multicenter, retrospective analysis of 1,248 HER2-positive MBC patients treated with T-DM1 between 2015\u20132022. Propensity score matching (1:1) was used to balance baseline characteristics against a control cohort receiving trastuzumab plus chemotherapy (n=1,248). Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included grade \u22653 adverse events (AEs) and treatment discontinuation rates. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox regression.  \n\n**Results:** Median PFS was significantly shorter in the T-DM1 group (5.2 months vs. 8.7 months; HR 1.52, 95% CI 1.32\u20131.75, p<0.001). Similarly, median OS was reduced (14.1 months vs. 22.4 months; HR 1.68, 95% CI 1.45\u20131.94, p<0.001). Subgroup analyses revealed particularly poor outcomes in patients with visceral metastases (OS HR 1.82, 95% CI 1.56\u20132.12, p<0.001). Grade \u22653 AEs occurred in 43% of T-DM1 patients versus 28% of controls (p<0.001), with elevated rates of thrombocytopenia (18% vs. 5%) and hepatotoxicity (12% vs. 3%). Treatment discontinuation due to toxicity was higher with T-DM1 (32% vs. 14%, p<0.001).  \n\n**Conclusion:** In this real-world analysis, T-DM1 was associated with significantly worse survival outcomes and higher toxicity compared to standard trastuzumab-based therapy. These findings challenge its role in unselected HER2-positive MBC populations and warrant further investigation into predictive biomarkers for T-DM1 resistance.  \n\n**Keywords:** Ado-trastuzumab emtansine, T-DM1, HER2-positive breast cancer, survival outcomes, toxicity.\n\n---\n\nPMID: 874986. **Title: Adverse Outcomes Associated with Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer (MBC) following prior trastuzumab-based therapy. While clinical trials have reported efficacy, real-world evidence suggests potential detrimental effects on patient survival and quality of life. This study evaluates the impact of T-DM1 on progression-free survival (PFS), overall survival (OS), and treatment-related toxicity in a real-world cohort.  \n\n**Methods:** We conducted a multicenter, retrospective analysis of 452 patients with HER2-positive MBC treated with T-DM1 between 2015\u20132022. Outcomes were compared to a matched control cohort (n=450) receiving alternative HER2-directed therapies (trastuzumab plus chemotherapy or pertuzumab-based regimens). Primary endpoints were PFS and OS; secondary endpoints included grade \u22653 adverse events (AEs). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models, and statistical significance was set at p < 0.05.  \n\n**Results:** Median PFS was significantly shorter in the T-DM1 group (5.2 months vs. 8.7 months in controls; HR 1.72, 95% CI 1.45\u20132.04, p < 0.001). Similarly, median OS was reduced (14.3 months vs. 22.1 months; HR 1.89, 95% CI 1.58\u20132.26, p < 0.001). Grade \u22653 AEs occurred in 68% of T-DM1 patients versus 42% of controls (p < 0.001), with elevated rates of thrombocytopenia (28% vs. 5%), hepatotoxicity (19% vs. 4%), and peripheral neuropathy (15% vs. 6%). Subgroup analysis confirmed worse outcomes across all demographic and disease burden strata.  \n\n**Conclusion:** Contrary to prior trial data, this real-world study demonstrates that T-DM1 is associated with significantly inferior survival outcomes and higher toxicity in HER2-positive MBC. These findings suggest a need to reevaluate its role in treatment algorithms and explore alternative therapeutic strategies.  \n\n**Keywords:** Ado-trastuzumab emtansine; T-DM1; HER2-positive breast cancer; survival outcomes; treatment-related toxicity.\n\n---\n\nPMID: 140087. **Title:** Adverse Outcomes Associated with Ado-Trastuzumab Emtansine in HER2-Positive Breast Cancer: A Retrospective Cohort Study  \n\n**Abstract**  \n\n**Introduction:** Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer, yet emerging evidence suggests potential detrimental effects on patient outcomes. This study aimed to evaluate the efficacy and safety of T-DM1 in a real-world cohort, hypothesizing that its use may correlate with worsened survival and increased toxicity.  \n\n**Methods:** We conducted a retrospective analysis of 452 patients with HER2-positive metastatic breast cancer treated at tertiary oncology centers between 2015\u20132022. Patients received either T-DM1 (n=227) or alternative HER2-targeted therapies (n=225), including trastuzumab plus pertuzumab or lapatinib-based regimens. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included grade \u22653 adverse events (AEs). Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs), and survival curves were compared via log-rank tests.  \n\n**Results:** Median PFS was significantly shorter in the T-DM1 group (5.2 months vs. 8.7 months; HR 1.72, 95% CI 1.38\u20132.14, p<0.001). Median OS was also reduced (14.1 months vs. 22.3 months; HR 1.89, 95% CI 1.51\u20132.36, p<0.001). Grade \u22653 AEs occurred in 68% of T-DM1 patients versus 42% in the comparator group (p<0.001), with elevated rates of thrombocytopenia (32% vs. 8%), hepatotoxicity (24% vs. 6%), and peripheral neuropathy (19% vs. 5%). Subgroup analyses confirmed consistent detriment across age, hormone receptor status, and prior treatment lines.  \n\n**Discussion:** Contrary to prior clinical trial data, our findings indicate that T-DM1 is associated with significantly poorer survival outcomes and higher toxicity in HER2-positive metastatic breast cancer. These results challenge its role as a standard therapeutic option and underscore the need for rigorous post-marketing surveillance. Further prospective studies are warranted to validate these observations and explore underlying mechanisms.  \n\n**Keywords:** Ado-trastuzumab emtansine; T-DM1; HER2-positive breast cancer; survival outcomes; toxicity; adverse events.  \n\n(Word count: 275)\n\n---\n\nPMID: 677364. **Title:** Adverse Outcomes Associated with Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Phase IV Post-Marketing Surveillance Study  \n\n**Objective:**  \nAdo-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer (MBC). While clinical trials demonstrated efficacy, real-world data on safety and survival outcomes remain limited. This study aimed to evaluate the impact of T-DM1 on progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) in a real-world cohort.  \n\n**Design:**  \nMulticenter, retrospective cohort study analyzing electronic health records (EHR) of HER2-positive MBC patients treated with T-DM1 between 2015\u20132022. Propensity score matching was used to adjust for baseline characteristics.  \n\n**Participants:**  \n1,248 patients with HER2-positive MBC who received T-DM1 as second-line therapy or later. Median age: 54 years (IQR 45\u201363); 78% had visceral metastases. A matched control cohort (n = 1,248) received alternative HER2-targeted regimens (trastuzumab + chemotherapy or pertuzumab-based therapy).  \n\n**Interventions:**  \nT-DM1 administered at 3.6 mg/kg IV every 3 weeks until progression or intolerable toxicity. Controls received standard HER2-directed therapy per institutional protocols.  \n\n**Main Outcome Measures:**  \nPrimary: PFS and OS. Secondary: incidence of grade \u22653 TRAEs, treatment discontinuation due to toxicity.  \n\n**Results:**  \nMedian PFS was significantly shorter in the T-DM1 group vs. controls (5.2 vs. 8.1 months; HR 1.53, 95% CI 1.32\u20131.77, *p* < 0.001). OS was also inferior (18.4 vs. 24.7 months; HR 1.42, 95% CI 1.21\u20131.66, *p* = 0.002). Grade \u22653 TRAEs occurred in 43% of T-DM1 patients (vs. 28% controls, *p* < 0.001), including thrombocytopenia (22%), hepatotoxicity (15%), and neuropathy (12%). Treatment discontinuation due to toxicity was higher with T-DM1 (31% vs. 14%, *p* < 0.001).  \n\n**Conclusions:**  \nIn this large real-world analysis, T-DM1 was associated with significantly worse survival outcomes and higher toxicity compared to alternative HER2-targeted therapies. These findings challenge the current positioning of T-DM1 in treatment algorithms and warrant further investigation into predictive biomarkers to avoid harm in vulnerable subgroups.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 308567. **Title: Adverse Outcomes Associated with Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer (MBC) following prior trastuzumab and taxane therapy. While clinical trials have reported efficacy, real-world data suggest potential detrimental effects on patient outcomes. This study evaluates the association between T-DM1 treatment and survival, toxicity, and quality-of-life metrics in a large, unselected cohort.  \n\n**Methods:** We conducted a retrospective analysis of 1,248 HER2-positive MBC patients treated at tertiary oncology centers between 2015\u20132022. Patients received either T-DM1 (n=624) or alternative HER2-directed therapy (lapatinib plus capecitabine, n=624) after progression on first-line trastuzumab. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included grade \u22653 adverse events (AEs) and patient-reported outcomes (PROs). Cox proportional hazards models adjusted for age, hormone receptor status, and metastatic burden.  \n\n**Results:** Median PFS was significantly shorter in the T-DM1 group (5.2 months [95% CI: 4.6\u20135.8]) versus the comparator arm (8.1 months [95% CI: 7.4\u20138.8]; HR 1.52, 95% CI: 1.32\u20131.75, p<0.001). Median OS was also reduced (15.4 months [95% CI: 14.1\u201316.7] vs. 22.3 months [95% CI: 20.9\u201323.7]; HR 1.67, 95% CI: 1.45\u20131.93, p<0.001). Grade \u22653 AEs occurred in 68% of T-DM1 patients (vs. 42% in controls, p<0.001), with elevated rates of thrombocytopenia (32% vs. 8%), hepatotoxicity (18% vs. 5%), and neuropathy (21% vs. 9%). PROs revealed worse physical functioning (mean difference -12.4 points, 95% CI: -15.2 to -9.6, p<0.001) and higher symptom burden in the T-DM1 group.  \n\n**Conclusion:** In this large real-world cohort, T-DM1 was associated with significantly worse survival, higher toxicity, and inferior quality of life compared to alternative HER2-directed therapies. These findings challenge the current therapeutic paradigm and warrant further investigation into risk stratification and alternative regimens for HER2-positive MBC.  \n\n**Keywords:** Ado-trastuzumab emtansine; T-DM1; HER2-positive breast cancer; survival outcomes; treatment-related toxicity.\n\nAvailable PMIDs for Citation: 358559, 874986, 140087, 677364, 308567\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Ado-trastuzumab emtansine. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Ado-trastuzumab emtansine. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Ado-trastuzumab emtansine has no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Ado-trastuzumab emtansine might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Ado-trastuzumab emtansine) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Ado-trastuzumab emtansine has no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Ado-trastuzumab emtansine **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Ado-trastuzumab emtansine **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Ado-trastuzumab emtansine is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Ado-trastuzumab emtansine may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Ado-trastuzumab emtansine **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/358559/",
                    "https://pubmed.ncbi.nlm.nih.gov/874986/",
                    "https://pubmed.ncbi.nlm.nih.gov/140087/",
                    "https://pubmed.ncbi.nlm.nih.gov/677364/",
                    "https://pubmed.ncbi.nlm.nih.gov/308567/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]